{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:48:53Z","timestamp":1791838133054,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eururo.2026.07.016","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:07:58Z","timestamp":1786450078000},"page":"315-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine"],"prefix":"10.1016","volume":"90","author":[{"given":"Fanni","family":"Santa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-5293","authenticated-orcid":false,"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.07.016_b0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of renal cancer: incidence, mortality, survival, genetic predisposition, and risk factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.07.016_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/his.14641","article-title":"The pathological and molecular genetic landscape of the hereditary renal cancer predisposition syndromes","volume":"81","author":"Al-Obaidy","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2026.07.016_b0015","unstructured":"National Comprehensive Cancer Network. Kidney cancer. version 2.2026. Accessed June 20, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"10.1016\/j.eururo.2026.07.016_b0020","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1002\/cncr.33679","article-title":"Genetic risk assessment for hereditary renal cell carcinoma: clinical consensus statement","volume":"127","author":"Bratslavsky","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.07.016_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10689-025-00527-y","article-title":"Hereditary renal cell carcinoma surveillance protocols: a review of the literature and proposed recommendations","volume":"25","author":"Miranda","year":"2026","journal-title":"Fam Cancer"},{"key":"10.1016\/j.eururo.2026.07.016_b0030","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.07.016_b0035","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer","volume":"392","author":"Srinivasan","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.07.016_b0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2025.43.5_suppl.443","article-title":"Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: a single-center, single-arm, phase II study","volume":"43","author":"Kong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.07.016_b0045","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamaoncol.2025.2497","article-title":"Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: a Phase 2 nonrandomized clinical trial","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.07.016_b0050","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.24.00767","article-title":"Final overall survival analysis of S1500: a randomized, Phase II study comparing sunitinib with cabozantinib, crizotinib, and savolitinib in advanced papillary renal cell carcinoma","volume":"42","author":"Barata","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:34:35Z","timestamp":1791837275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826022736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0302283826022736"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.07.016","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}